CTAD 2026

The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda.

The upcoming 19th annual CTAD conference (CTAD26) will take place in Boston, USA, from November 16-19, 2026. CTAD26 is poised to build on the momentum of previous years, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today.

At the recently concluded CTAD26 in San Diego (USA), over 2,750 international leaders convened to discuss groundbreaking developments in AD clinical research.

The CTAD scientific program is underpinned by a rigorous peer-review abstract selection process, ensuring the presentation of high-quality research that drives the field forward.

CTAD is also closely associated with the Journal of Prevention of Alzheimer’s Disease (JPAD), the conference’s official journal. JPAD publishes peer-reviewed articles, including reviews, original research, and short reports, on topics critical to Alzheimer’s prevention. These include neuroscience, biomarkers, imaging, epidemiology, public health, geroscience, physical and cognitive exercise, nutrition, risk and protective factors, drug development, trial design, and health economic outcomes. With a 2024 Impact Factor of 7.8, JPAD is a leading publication in the field..

CTAD and JPAD remain committed to advancing Alzheimer’s disease research and prevention, fostering collaboration among global leaders, and supporting the dissemination of innovative findings to improve patient outcomes